NovoCure Limited

NASDAQ:NVCR

Medical - Instruments & Supplies

Healthcare
$10.73 -19.66%

-$3.51 today

Market cap
$1.25B
Beta
0.92
P/E (TTM)
-9.5
EPS (TTM)
-$1.52
52W Low $9.82High $18.92

Volume 1.41M

Average 1.52M

NVCR Common Stock Issued

Cash raised by issuing new shares.

NovoCure LimitedNASDAQ: NVCR

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued declines year over year

Q1 FY2026 common stock issued of $390K fell 92.6% year over year, behind the -50.9% change in trailing-twelve-month common stock issued. Sequentially, it fell 75.6% from the prior quarter. Over 3 fiscal years it compounded at +23.2% a year.

Context

  • Common stock issued amounted to 1.5% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Common stock issued increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -92.6% toward the trailing-twelve-month pace of -50.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$390K-75.6% QoQ
Last fiscal yearDec 2025
$9.77M+135.4% YoY
LTMMar 2026
$4.66M-50.9% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-92.6%——
1 year+135.4%——
3-year CAGR+23.2%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
9.77M USD
Year-over-year change
+135.4%
4-year CAGR
+21.1%

Common Stock Issued vs competitors

How NVCR compares with its peers on the latest reported figures

  • NVCR's LTM Mar 2026 common stock issued of $4.66M is the 3rd largest of the 4 companies compared; the peer median is $18.41M.
  • Its year-over-year change of -50.9% is the 2nd highest of 4, against a peer median of -54.8%.
  • Common stock issued amounts to 0.7% of revenue for NVCR, versus a peer median of 20.4%.
NVCR Competitors Peer median
Common Stock Issued for NVCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLSEPulse Biosciences, Inc.LTM Jun 2026$56.66M -54.8%+4.9%4781.4%
DCTHDelcath Systems, Inc.LTM Mar 2026$18.41M +462.4%+24.7%20.4%
NVCRNovoCure LimitedLTM Mar 2026$4.66M -50.9%+23.2%0.7%
NPCENeuroPace, Inc.LTM Mar 2026$123K -99.8%—0.1%
Peer median (excluding NVCR) $18.41M-54.8%+14.8%20.4%

Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.35M)(92.53M)(207.04M)(168.63M)(136.23M)
Depreciation & Amortization10.25M10.62M10.97M(14.41M)14.65M
Deferred Income Tax3.88M0000
Stock-Based Compensation94.9M106.96M115.61M160.04M0
Change in Working Capital29.07M11.8M29.56M(4.3M)(15.13M)
Accounts Receivables5.27M2.55M29.41M(26.36M)(38.94M)
Inventory2.48M(4.34M)(8.92M)2.57M(5.67M)
Accounts Payables27.78M14.26M14.87M19.11M18.96M
Other Working Capital(6.46M)(666K)(5.8M)384K10.52M
Other Non-Cash Items3.01M(6.05M)(22.43M)932K87.67M
Operating Cash Flow82.76M30.79M(73.34M)(26.37M)(49.03M)
Capital Expenditures(24.17M)(21.36M)(27.09M)(42.86M)(26.65M)
Acquisitions (Net)120.66M118.6M000
Purchases of Investments(1.08B)(1.3B)(1B)(875.39M)(821.08M)
Sales of Investments958M1.18B1.21B778M1.29B
Other Investing Activities(120.66M)(118.6M)000
Investing Cash Flow(144.83M)(139.96M)184.15M(140.24M)437.28M
Debt Repayment(26K)(28K)(10K)84.01M(460.97M)
Common Stock Issued4.55M5.22M4.42M4.15M9.77M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities21.18M10.3M11.38M2.16M(146K)
Financing Cash Flow25.7M15.49M15.79M90.32M(451.34M)
Effect of Forex Changes(188K)(97K)131K(174K)394K
Net Change in Cash(36.56M)(93.78M)126.73M(76.47M)(62.7M)
Free Cash Flow58.59M9.43M(100.43M)(69.22M)(75.68M)

NovoCure Limited

NASDAQ:NVCR

Intrinsic Alpha fair value

Locked

Current Price

$10.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.